AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum



AbCellera Biologics (NASDAQ:ABCL) is working to evolve from a technology-enabled drug discovery partner into what the company described as an integrated biotech with internal programs advancing through mid- to late-stage development, according to comments from Senior Director of Strategic Finance an



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *